MedTrace Logo

Real-world Clinical Effectiveness of Whole Genome and Transcriptome Analysis to Guide Advanced Cancer Care

NCT04141397 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 1200

Last updated 2021-01-27

No results posted yet for this study

Summary

This study aims to determine the clinical effectiveness of whole-genome and transcriptome analysis (WGTA) to guide advanced cancer care. The study setting is the British Columbia (BC) Personalized OncoGenomics (POG) program, a single group research study of WGTA guiding treatment planning for patients with advanced, incurable cancers (NCT02155621). To characterize clinical effectiveness, the survival impacts of POG's approach compared to usual care in matched controls will be estimated.

Conditions

Interventions

GENETIC

Initiation of POG-related WGTA

POG-related WGTA generally involves collecting biopsy samples, applying whole-genome and transcriptome sequencing, and using bioinformatics analysis to interpret sequence data and inform clinical decision-making.

GENETIC

Usual care

Usual care, not involving the initiation of POG-related WGTA

Sponsors & Collaborators

  • BC Cancer Foundation

    collaborator OTHER

  • Genome British Columbia

    collaborator INDUSTRY

  • British Columbia Cancer Agency

    lead OTHER

Eligibility

Min Age
19 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-07-01
Primary Completion
2018-12-31
Completion
2021-12-31

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04141397 on ClinicalTrials.gov